Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 186Carcinoma, Non-Small-Cell Lung 144Multiple Myeloma 120Prostatic Neoplasms 118Leukemia, Myeloid, Acute 77Neoplasms 75Colorectal Neoplasms 75Melanoma 72Neoplasm Metastasis 66Lymphoma 66Squamous Cell Carcinoma of Head and Neck 64Lung Neoplasms 64Pancreatic Neoplasms 54Ovarian Neoplasms 50Sarcoma 46Carcinoma, Renal Cell 45Triple Negative Breast Neoplasms 43Glioblastoma 42Urinary Bladder Neoplasms 41Leukemia, Lymphocytic, Chronic, B-Cell 41Carcinoma, Hepatocellular 41Recurrence 40Head and Neck Neoplasms 38Hematologic Neoplasms 37Lymphoma, Large B-Cell, Diffuse 36Precursor Cell Lymphoblastic Leukemia-Lymphoma 35Myelodysplastic Syndromes 35Lymphoma, Non-Hodgkin 34Brain Neoplasms 34Lymphoma, Mantle-Cell 31

Interventions

padeliporfin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Active not recruiting × Localized Prostate Cancer × Clear all
NCT03315754 2024-12-20

Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer.

Steba Biotech S.A.

Phase 2 Active not recruiting
50 enrolled 8 charts
Genitourinary

Localized Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡